Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg

NCT03350295 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
48
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Bayer